Drug therapy of non-insulin-dependent diabetes mellitus in the elderly

Drugs

Volumn 51, Issue 6, 1996, Pages 931-941

  Mooradian, Arshag D ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; CIGLITAZONE; GLIBENCLAMIDE; GLIPIZIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

ADULT; AGED; DRUG CONTRAINDICATION; DRUG COST; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOGLYCEMIA; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; REVIEW; WEIGHT GAIN;

EID: 0029989710     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651060-00002     Document Type: Review

References (57)

1. Morley JE, Mooradian AD, Rosenthal MJ, et al. Diabetes mellitus in elderly patients: is it different? Am J Med 1987; 83: 533-44
2. Mooradian AD. Management of diabetes in elderly. In: Morley JE, Korenman SG, editors. Endocrinology and metabolism in the elderly. Boston: Blackwell Scientific Publications, 1992; 388-405
3. Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 years. Diabetes 1987; 38: 523-34
4. Rosenthal MJ, Morley JE. Diabetes and its complications in older people. In: Morley JE, Korenman SG, editors. Endocrinology and metabolism in the elderly. Boston (MA): Blackwell Scientific Publications. 1992: 373-87
5. Ferner RH. Oral hypoglycemic agents. Med Clin North Am 1988; 72: 1323-35
6. Melander A, Bitzen PO, Faber O, et al. Sulfonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58-72
7. Gerich JH. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-45
8. Groop L. Sulfonylureas in NIDDM. Diabetes Care 1992; 18: 737-54
9. Mooradian AD. The effect of sulfonylureas on the in vivo tissue uptake of glucose in normal rats. Diabetologia 1987; 30: 120-1
10. Campbell IW. Sulfonylureas and metformin: efficacy and inadequacy In: Bailey CJ, Flatt PR, editors. New antidiabetic drugs. London: Smith, Gordon, Nishimura, 1990: 33-51
11. Krall LP. The treatments of NIDDM in the decade of 90s. Diabetes Res Clin Pract 1991; 14 Suppl. 2: 515-9
12. Lebovitz HH. Are oral hypoglycemic agents likely to benefit NIDDM patients? Hosp Pract 1992; 27 Suppl. 1: 26-31
13. Ziegler O, Drouin P. Hemobiological activity of gliclazide in diabetes mellitus. Diabetes Res Clin Pract 1991; 14 Suppl. 2: 583-9
14. Lebovitz HE. Pasmantier R. Combination insulin-sulfonylurea therapy. Diabetes Care 1990; 13: 667-75
15. Berelowitz M, Fischette C, Cefalu W, et al. Comparative efficacy of a once daily controlled release formalation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994; 17: 1460-4
16. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989; 12: 203-8
17. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8
18. Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res 1985; 15 Suppl.: 111-5
19. Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res 1985; 15 Suppl.: 105-11
20. Asplund K, Wilholm B-E, Lithner F. Glibenelamide associated hypoglycemia: a report on 57 cases. Diabelotogia 1983; 24: 412-7
21. Asplund K, Wilholm B-E, Lundman B. Severe hypoglycemia during treatment with glipizide. Diabet Med 1991; 8: 726-31
22. Ferner RE, Neil HAW. Sulfonylureas and hypoglycemia. BMJ 1988; 296: 949-50
23. Baily CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
24. Wu MS, Johnston P, Shew WHH, et al. Effect of melformin on carbohydrate lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8
25. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of melformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-8
26. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-4
27. Bailey CJ. Melformin: an update. Gen Pharmacol 1993; 24: 1299-309
28. Bailey CJ, Nattrass M. Treatment melformin Baillieres Clin Endocrinol Metab 1988; 2: 455-76
29. Batley CJ, Lord JM, Atkins TW. The insulin receptor and diabetes. In: Nattrass M, Santiago JV, editors Recent advances in diabetes. Edinburgh: Churchill Livingstone. 1984: 27-44
30. Klip A, Sarabia V, Ramlal T, el al. Glucose transport in human muscle cells in culture: stimulation by insulin and metformin [abstract]. Diabetes 1990; 39 Suppl. 1: 82A
31. Sirtori CR, Franceshini G, Gianfranschi G, et al. Melformin improves peripheral vascular flow in non-hyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 1984; 6: 914-23
32. Vague P, Julian-Vague I, Alessi MC, et al. Metformin decreases the high plasminogen activator capacity plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57: 326-8
33. DeFronzo RA, Goodman AM and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9
34. Mooradian D, Kalis J, Nugent CA. The nutritional stains of ambulatory elderly type II diabetic patients. Age 1990; 13: 87-9
35. Mooradian AD, Osterweil D, Petrasek D, et al. Diabetes mellitus in elderly nursing home patients: a survey of clinical characteristics and management. J Am Geriatr Soc 1988; 36: 391-6
36. Reed RL, Mooradian AD. Nutritional status and dietary management of elderly diabetic patients. Clin Geriatr Med 1990; 6: 883-901
37. Dandona P, Fonseca V, Mier A, et al. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983; 6: 472-4
38. Tomkin G. Malabsorption of vitamin B12 in diabetic patients treated with phenformin: a comparison with metformin. BMJ 1973; 111: 673-5
39. Bergman U, Boman G, Wilholm BE. Epidemiology of adverse drug reactions to phenformin and metformin. BMJ 1978; 11: 464-466
40. Nattrass M, Alberti KGMM. Biguanides. Diabetologia 1978; 14: 71-4
41. Jenkins DJA, Taylor RH, Goff DJ, et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981; 30: 951-4
42. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988; 35: 214-43
43. Hollander P. Safety profile of acarbose, an α-glucosidase inhibitor. Drugs 1990; 44 Suppl. 3: 47-53
44. Chaisson J-L, Josse RG, Hunt J A, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121: 928-35
45. Hoffman J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM. Diabetes Care 1994; 17: 561-6
46. Kosaka K, Kuzuya T, Akanuma Y, et al. Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by diet alone: a double-blind placebo controlled study. J Clin Ther Med 1993; 9 Suppl. 3: 61-9.3
47. Kosaka K, Kuzuya T, Akanuma Y, et al. Clinical evaluation of a new hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by sulfonylureas: a double-blind placebo, controlled study. J Clin Ther Med 1993; 9 Suppl. 3: 95-126
48. Akanuma Y, Kosaka K, Kuzuya K, et al. Long term study of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus. J Clin Ther Med 1993; 9 Suppl. 3: 127-49
49. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of a new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203
50. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-22
51. Thompson RG. Gottlieb AB, Organ K, et al. The human amylin analogue (AC 137) reduces glucose following sustacal in patients with Type II diabetes (abstract). Diabetes 1995; 44: 127A
52. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys (B28), pro (B29)]- human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402
53. Mooradian AD, Failla M, Hoogwerf B, et al. Selected vitamins and minerals in diabetes. Diabetes Care 1994; 17: 464-79
54. Knuiman MW, Welborn TA, McCann VJ, et al. Prevalence of diabetic complications in relation to risk factors. Diabetes 1986; 35: 1332-9
55. Campbell S, Mooradian AD, Diabetes mellitus. In: Bressler R, Katz MD, editors. Geriatric pharmacology. New York: McGraw Hill Inc., 1993: 409-25
56. Hermann LS, Schersten B, Bitzen P-O, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double blind controlled study. Diabetes Care 1994; 17: 1100-9
57. Mooradian AD. Biological and functional definition of the older patient: the role of biomarkers of aging. Oncology 1992; 6 Suppl.: 39-44